Drugs to treat diabetes, heart disease and blood cancers among people affected by price negotiations

THE Biden Administration says Medicare beneficiaries will save about $1.5 billion in direct drug costs to treat diabetes, heart disease, types of arthritis and other illnesses under new prices negotiated with pharmaceutical companies that will come into force in 2026.

Savings range from 79% for Januvia, used to treat diabetes, to 38% for Imbruvica, used to treat blood cancers. This is the cost of the drug before any discounts or rebates are applied, but not the price people actually pay when filling their prescriptions.

A look at medications and negotiated prices.

Manufacturer: Merck Sharp Dohme

Conditions: Diabetes

Negotiated price: $113 for a 30-day supply

Reduction: 79%

Manufacturer: Novo Norodisk

Conditions: Diabetes

Negotiated price: $119 for a 30-day supply

Reduction: 76%

Manufacturer: AstraZeneca AB.

Conditions: Diabetes, heart failure and chronic kidney disease

Negotiated price: $178.50 for a 30-day supply

Reduction: 68%

Manufacturer: Immunex Corp.

Conditions: Rheumatoid arthritis, psoriasis, and psoriatic arthritis

Negotiated price: $2,355 for a 30-day supply

Reduction: 67%

Manufacturer: Boehringer Ingelheim

Conditions: Diabetes, heart failure and chronic kidney disease

Negotiated price: $197 for a 30-day supply

Reduction: 66%

Manufacturer: Janssen Biotech Inc.

Conditions: Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis

Negotiated price: $4,695 for a 30-day supply

Reduction: 66%

Manufacturer: Janssen Pharms

Conditions: Prevention and treatment of blood clots. Risk reduction for patients with coronary or peripheral artery disease

Negotiated price: $197 for a 30-day supply

Reduction: 62%

Manufacturer: Bristol Myers Squibb

Conditions: Prevention and treatment of blood clots

Negotiated price: $231 for a 30-day supply

Reduction: 56%

Manufacturer: Novartis Pharms Corp.

Conditions: Heart failure

Negotiated price: $295 for a 30-day supply

Reduction: 53%

Manufacturer: Farmacíclica LLC

Conditions: blood cancer

Negotiated price: $9,319 for a 30-day supply

Savings: 38%